BR0009446A - Composto, processo para preparar o mesmo, composição uso de um composto, e, métodos para o tratamento ou a prevenção de uma doença em um mamìfero, para o tratamento ou a prevenção de asma em um mamìfero e para o tratamento ou a prevenção de doença pulmonar obstrutiva crÈnica em um mamìfero - Google Patents

Composto, processo para preparar o mesmo, composição uso de um composto, e, métodos para o tratamento ou a prevenção de uma doença em um mamìfero, para o tratamento ou a prevenção de asma em um mamìfero e para o tratamento ou a prevenção de doença pulmonar obstrutiva crÈnica em um mamìfero

Info

Publication number
BR0009446A
BR0009446A BR0009446-3A BR0009446A BR0009446A BR 0009446 A BR0009446 A BR 0009446A BR 0009446 A BR0009446 A BR 0009446A BR 0009446 A BR0009446 A BR 0009446A
Authority
BR
Brazil
Prior art keywords
mammal
prevention
treatment
disease
compound
Prior art date
Application number
BR0009446-3A
Other languages
English (en)
Other versions
BRPI0009446B1 (pt
BRPI0009446B8 (pt
Inventor
Alexander William Oxford
David Jack
Original Assignee
Vernalis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9907454.4A external-priority patent/GB9907454D0/en
Priority claimed from GBGB9909802.2A external-priority patent/GB9909802D0/en
Application filed by Vernalis Ltd filed Critical Vernalis Ltd
Publication of BR0009446A publication Critical patent/BR0009446A/pt
Publication of BRPI0009446B1 publication Critical patent/BRPI0009446B1/pt
Publication of BRPI0009446B8 publication Critical patent/BRPI0009446B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PREPARAR O MESMO, COMPOSIçãO, USO DE UM COMPOSTO, E, MéTODOS PARA O TRATAMENTO OU A PREVENçãO DE UMA DOENçA EM UM MAMìFERO, PARA O TRATAMENTO OU A PREVENçãO DE ASMA EM UM MAMìFERO E PARA O TRATAMENTO OU A PREVENçãO DE DOENçA PULMONAR OBSTRUTIVA CRÈNICA EM UM MAMìFERO". Compostos de fórmula geral (1) em que cada um R^ 1^ e R^ 2^ representa independentemente um grupo C~ 1-6~ alquila ou C~ 2-7~ acila; W representa um átomo de hidrogênio ou um grupo C~ 1-3~ alquila, C~ 2-3~ alquenila ou C~ 2-3~ alquinila; R^ 6^ representa um átomo de hidrogênio ou um gmpo C~ 1-6~ alquila, C2-6 alquenila, C~ 2-6~ alquinila, amino, C~ 1-6~ alquilamino, di(C~ 1-6~) alquilamino OU C~ 2-7~ acilamino; cada um dentre IC e R8 representa independentemente um átomo de hidrogênio ou halogênio ou um hidróxi, trifluorometila, C1-6 alquila, C~ 2-6~ alquenila, C~ 2-6~ alquinila, C~ 2-7~ acila, C~ 1-6~ alquiltio, C~ 1-6~ alcóxi ou C~ 3-6~ cicloalquila; e R^ 9^ representa um átomo de hidrogênio ou halogênio ou um grupo hidróxi, trifluorometila, C~ 1-6~ alquila, C~ 2-6~ alquenila, C~ 2-6~ alquinila, C~ 2-7~ acila, C~ 1-6~ alquiltio, C~ 1-6~ alcóxi ou C~ 3-6~ cicloalquila; X representa OCH~ 2~ ou um grupo CR^ 3^R^ 4^, em que cada um dentre R^ 3^ e R^ 4^ representa independentemente um átomo de hidrogênio ou um grupo C~ 1-3~ alquila; cada um dentre R^ 10^ e R^ 11^ representa indepentemente um átomo de hidrogênio, um grupo C~ 1-3~ alquila, C~ 3-6~ cicloalquila ou fenila; y representa um átomo de oxigênio ou um grupo CHNO~ 2~, NCN, NH ou NNO~ 2~; n é um número inteiro de 2 a 4; ou um sal do mesmo; são úteis para tratamento de distúrbios respiratórios, como asma. Compostos da invenção apresentam uma maior duração de ação do que o conhecido composto trequinsina (9, 10-dimetóxi-3-metil-2-mesitilimino-2,3,6,7-tetraidro-4Hpirimido[6,1-a]is oquinolin-4-ona) e não apresentam o sabor muito amargo da trequinsina.
BRPI0009446A 1999-03-31 2000-03-29 composto derivado de pirimido [6,1-a] isoquinolin-4-ona, processo para preparar p mesmo, composição, e, uso de um composto BRPI0009446B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9907454.4A GB9907454D0 (en) 1999-03-31 1999-03-31 Compounds
GBGB9909802.2A GB9909802D0 (en) 1999-04-28 1999-04-28 Compounds
PCT/GB2000/001193 WO2000058308A1 (en) 1999-03-31 2000-03-29 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE

Publications (3)

Publication Number Publication Date
BR0009446A true BR0009446A (pt) 2002-01-15
BRPI0009446B1 BRPI0009446B1 (pt) 2016-11-01
BRPI0009446B8 BRPI0009446B8 (pt) 2021-05-25

Family

ID=26315369

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009446A BRPI0009446B8 (pt) 1999-03-31 2000-03-29 composto derivado de pirimido [6,1-a] isoquinolin-4-ona, processo para preparar p mesmo, composição, e, uso de um composto

Country Status (16)

Country Link
US (5) US6794391B2 (pt)
EP (1) EP1165558B1 (pt)
JP (1) JP4685243B2 (pt)
CN (1) CN100415743C (pt)
AT (1) ATE250602T1 (pt)
AU (1) AU773504B2 (pt)
BR (1) BRPI0009446B8 (pt)
CA (1) CA2368413C (pt)
DE (1) DE60005493T2 (pt)
DK (1) DK1165558T3 (pt)
ES (1) ES2208310T3 (pt)
MX (1) MXPA01009846A (pt)
NO (1) NO20014728L (pt)
NZ (1) NZ514158A (pt)
PT (1) PT1165558E (pt)
WO (1) WO2000058308A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368413C (en) * 1999-03-31 2008-07-29 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
CA2611907A1 (en) * 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
EP2138495A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
KR101860968B1 (ko) * 2010-08-09 2018-05-24 베로나 파마 피엘씨 피리미도[6,1-ａ]이소퀴놀린-4-원 화합물의 결정 형태
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
HUE048020T2 (hu) * 2014-05-12 2020-05-28 Verona Pharma Plc Új kezelés
CN111249260B (zh) 2014-09-15 2023-01-10 维罗纳制药公司 包含rpl554的液体吸入制剂
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) * 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
EP3822272A4 (en) 2018-07-13 2022-04-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CONDENSED TRICYCLIC COMPOUND AS PDE3/PDE4 DOUBLE INHIBITOR
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
WO2021143843A1 (zh) * 2020-01-15 2021-07-22 正大天晴药业集团股份有限公司 一种pde3/pde4双重抑制剂的结晶及其应用
WO2021143841A1 (zh) 2020-01-15 2021-07-22 正大天晴药业集团股份有限公司 三并环类pde3/pde4双重抑制剂化合物的药物组合物
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
KR20240004495A (ko) 2021-04-29 2024-01-11 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 이소퀴놀론 화합물과 이의 용도
WO2023076205A1 (en) 2021-10-29 2023-05-04 Teva Pharmaceuticals International Gmbh Solid state forms of ensifentrine and process for preparation thereof
WO2023109802A1 (zh) * 2021-12-14 2023-06-22 海思科医药集团股份有限公司 三环稠杂环类pde3/4双重抑制及其用途
WO2023138676A1 (zh) * 2022-01-21 2023-07-27 四川海思科制药有限公司 三环稠杂环类pde3/4双重抑制及其用途
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024033624A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd)
WO2024033627A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Liquid pharmaceutical composition
WO2024084212A1 (en) 2022-10-20 2024-04-25 Verona Pharma Plc Treatment of idiopatic pulmonary fibrosis with ensifentrine
WO2024088402A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的晶型及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ185900A (en) * 1976-12-10 1981-04-24 Hoechst Ag Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4254121A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 3-Oxo-5H-pyrimido[2,1-c][1,4 ]benzoxazines
US4307092A (en) * 1979-08-13 1981-12-22 Ayerst Mckenna & Harrison, Inc. 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters
US4254118A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1-Oxo-5H-pyrimido[2,1-c][1,4]benzthiazine-2-carboxylic acid esters
CA1237429A (en) * 1983-05-05 1988-05-31 Frank Kienzle Pyrimidone derivatives
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE3816995A1 (de) * 1988-05-19 1989-11-23 Hoechst Ag Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10287655A (ja) * 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
CA2368413C (en) * 1999-03-31 2008-07-29 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one

Also Published As

Publication number Publication date
BRPI0009446B1 (pt) 2016-11-01
US20040171828A1 (en) 2004-09-02
CN100415743C (zh) 2008-09-03
CA2368413A1 (en) 2000-10-05
DE60005493T2 (de) 2004-07-01
US7378424B2 (en) 2008-05-27
AU4127400A (en) 2000-10-16
DK1165558T3 (da) 2004-02-09
ES2208310T3 (es) 2004-06-16
AU773504B2 (en) 2004-05-27
BRPI0009446B8 (pt) 2021-05-25
NO20014728D0 (no) 2001-09-28
MXPA01009846A (es) 2003-06-24
JP4685243B2 (ja) 2011-05-18
WO2000058308A1 (en) 2000-10-05
EP1165558B1 (en) 2003-09-24
US6794391B2 (en) 2004-09-21
EP1165558A1 (en) 2002-01-02
DE60005493D1 (de) 2003-10-30
NO20014728L (no) 2001-11-23
US7105663B2 (en) 2006-09-12
JP2002540207A (ja) 2002-11-26
US20040176353A1 (en) 2004-09-09
CA2368413C (en) 2008-07-29
PT1165558E (pt) 2004-02-27
CN1348453A (zh) 2002-05-08
US20030036542A1 (en) 2003-02-20
ATE250602T1 (de) 2003-10-15
US8242127B2 (en) 2012-08-14
NZ514158A (en) 2000-03-29
US20120302533A1 (en) 2012-11-29
US20080206163A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
BR0009446A (pt) Composto, processo para preparar o mesmo, composição uso de um composto, e, métodos para o tratamento ou a prevenção de uma doença em um mamìfero, para o tratamento ou a prevenção de asma em um mamìfero e para o tratamento ou a prevenção de doença pulmonar obstrutiva crÈnica em um mamìfero
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
BR9712314A (pt) Método de uso de inibidores de ciclooxigenase-2 no tratamento e prevenção de neoplasia
HUP0500163A3 (en) Pyrazolo [5,1-b]quinazoline derivatives and pharmaceutical compositions thereof as inhibitors of impdh enzyme
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
BR9714059A (pt) S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
BR0312464A (pt) Inibidores de tirosina quinases
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
WO1998056771A3 (en) Piperazine derivatives and their use as anti-inflammatory agents
BRPI0511424A (pt) composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
CA2379560A1 (en) Purine derivatives inhibitors of tyrosine protein kinase syk
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
HUP0004211A2 (hu) PDE-5 inhibitorok alkalmazása tüdõ magas vérnyomás kezelésére szolgáló gyógyszerkészítmények elõállítására
CA2165433A1 (en) Novel chemical compounds having pde-iv inhibition activity
AU5783300A (en) Anilinoquinazolines as protein tyrosine kinase inhibitors
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
BR0206935A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
AU3734999A (en) Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
BR0009847A (pt) Kit de partes, método de preparação de um kit de partes, formulação farmacêutica, método de tratamento de uma condição na qual inibição de trombina é requerida ou desejada, e, uso de um inibidor de trombina, ou de um derivado farmaceuticamente aceitável do mesmo
BR9814080A (pt) Uso de compostos para atividade anti-prurìtica

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 471/04, A61K 31/519, C07D 498/04, A61K 31/553, A61P 11/00

Ipc: C07D 471/04 (2009.01), A61K 31/519 (2009.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: VERNALIS DEVELOPMENT LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: VERNALIS DEVELOPMENT LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: RHINOPHARMA LIMITED (CA)

B25A Requested transfer of rights approved

Owner name: VERONA PHARMA PLC. (GB)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/11/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/03/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/03/2020